FDA Approves First Nasal Spray For Dry Eye Disease From Oyster Point Pharma

The FDA has approved Oyster Point Pharma Inc OYST Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for signs and symptoms of dry eye disease.
Tyrvaya Nasal Spray is the first and only nasal spray approved for dry eye disease.
Related: Oyster Point Inks License Pact With Ji Xing Pharma For Dry Eye Disease Candidates In Greater China.
Tyrvaya binds to cholinergic receptors to activate the trigeminal parasympathetic pathway resulting in increased production of the basal tear film as a treatment for dry eye disease.
Tyrvaya will be available from next month in cartons containing two multidose nasal spray bottles.
Each nasal spray bottle covers treatment for 15 days, administered twice daily into each nostril.
Related content: Benzinga's Full FDA Calendar.
Price Action: OYST shares closed 1.91% higher at $13.86 on Monday.